UBS cuts Salesforce stock price target to $300, maintains neutral

UBS lowered its price target on Salesforce (CRM) to $300 from $320, maintaining a Neutral rating, citing potential risks associated with M&A execution, specifically a possible bid for Informatica. The analyst's assessment follows Salesforce's World Tour event and a media report hinting at renewed acquisition interest, with the new target reflecting an 18x multiple on free cash flow estimates. Other firms have reiterated Buy/Outperform ratings with higher price targets, emphasizing the transformative potential of the Informatica acquisition and Salesforce's strategic focus on regulated industries.

Analysis

UBS analyst Karl Keirstead revised Salesforce's (CRM) price target to $300 from $320, maintaining a Neutral rating, primarily citing potential M&A execution risks associated with a then-speculated renewed bid for Informatica, following Salesforce's World Tour event showcasing its Agentforce and Data Cloud services. Keirstead noted Agentforce adoption is in early stages and values Salesforce at 16 times estimated CY26/FY27 free cash flow (FCF), applying an 18x multiple for the new target, which is below peer averages. Salesforce, currently trading at $275.22 with a $264 billion market cap, reports $37.9 billion in annual revenue and impressive 77% gross profit margins, operating with moderate debt. Crucially, the article subsequently clarifies that Salesforce has indeed announced the acquisition of Informatica. This development shifts the M&A concern from a potential bid to the execution of a confirmed deal. While UBS expresses caution, other financial institutions maintain a more bullish outlook: Truist Securities holds a Buy rating with a $400 target, citing the Informatica deal's transformative potential; Evercore ISI an Outperform with a $350 target for strategic alignment; BMO Capital Markets an Outperform with a $350 target; Goldman Sachs a Buy with a $340 target, projecting a 7% revenue increase and a 10% rise in current remaining performance obligations for the upcoming fiscal year; and Stifel a Buy with a $375 target, highlighting product updates. These firms generally view the Informatica acquisition, aimed at enhancing data management capabilities and expected to be accretive to non-GAAP operating margin and EPS from the second year, as a strategic positive. Salesforce is focused on this integration and enhancing offerings in regulated industries like Financial Services and Healthcare, with analysts closely monitoring its performance and strategies ahead of the upcoming earnings report.

Key Decisions for Investors

• Investors should weigh UBS's Neutral stance and concerns regarding Informatica M&A execution risk against the more broadly positive consensus from other analysts who see strategic merit and accretion potential in the confirmed acquisition.
• Closely monitor Salesforce's upcoming earnings report for specific updates on the Informatica integration timeline, synergy realization, management's financial outlook, and the adoption trajectory of new services like Agentforce.
• Consider Salesforce's current valuation, noted by UBS as 16x estimated CY26/FY27 FCF and at the lower end of its peer range, in conjunction with its growth catalysts including the Informatica acquisition, new product offerings, and expansion in regulated industries, balanced against potential macroeconomic headwinds and M&A integration challenges.